Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence

Journal of Women's Health

Volumn 20, Issue 8, 2011, Pages 1245-1255

  Iavazzo, Christos ^a   Gkegkes, Ioannis D ^a   Zarkada, Ioanna M ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; BORIC ACID; BUTOCONAZOLE; CLOTRIMAZOLE; CRYSTAL VIOLET; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; TERCONAZOLE;

CANDIDA; ERYTHEMA; FUNGAL STRAIN; HUMAN; MONOTHERAPY; MYCOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL BURNING SENSATION; VAGINAL ERYTHEMA; YEAST;

ADMINISTRATION, INTRAVAGINAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; AZOLES; BIOLOGICAL AVAILABILITY; BORIC ACIDS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; CASE-CONTROL STUDIES; DRUG RESISTANCE, MULTIPLE, FUNGAL; FEMALE; FLUCYTOSINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SUPPOSITORIES; TREATMENT OUTCOME; VAGINAL DISEASES;

EID: 80051747324     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2708     Document Type: Review

References (50)

1. das Neves J, Pinto E, Teixeira B, et al. Local treatment of vulvovaginal candidosis: General and practical considerations. Drugs 2008;68:1787-1802.
2. Nyirjesy P, Weitz MV, Grody MH, Lorber B. Over-thecounter and alternative medicines in the treatment of chronic vaginal symptoms. Obstet Gynecol 1997;90:50-53. (Pubitemid 27272955)
3. Saporiti AM, Gomez D, Levalle S, et al. [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use.] Rev Argent Microbiol 2001;33:217-222. (Pubitemid 34230012)
4. Watson C, Calabretto H. Comprehensive review of conventional and nonconventional methods of management of recurrent vulvovaginal candidiasis. Aust NZ J Obstet Gynaecol 2007;47:262-272. (Pubitemid 47079552)
5. Nyirjesy P. Chronic vulvovaginal candidiasis. Am Fam Physician 2001;63:697-702. (Pubitemid 32178694)
6. Mardh PA, Rodrigues AG, Genc M, Novikova N, Martinezde- Oliveira J, Guaschino S. Facts and myths on recurrent vulvovaginal candidosis-A review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002;13:522-539. (Pubitemid 34816236)
7. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;178:203-211. (Pubitemid 28124116)
8. Budavari S. Merck index: An encyclopedia of chemicals, drugs, and biologicals, 12th ed. Whitehouse Station, NJ: Merck & Co., 1996.
9. Baselt R. Disposition of toxic drugs and chemicals in man, 7th ed. Foster City, CA: Biomedical Publications, 2004.
10. Prutting SM, Cerveny JD. Boric acid vaginal suppositories: A brief review. Infect Dis Obstet Gynecol 1998;6:191-194. (Pubitemid 28507051)
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
12. Dean A, Sullivan K, Soe M, OpenEpi: Open source epidemiologic statistics for public health, version 2.2.1. Updated April 6, 2008. Available at www.OpenEpi.com Accessed September 18, 2008.
13. Ray D, Goswami R, Banerjee U, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007;30:312-317. (Pubitemid 46198336)
14. Dorrell L, Edwards A. Vulvovaginitis due to fluconazole resistant Candida albicans following self-treatment with nonprescribed triazoles. Sex Transm Infect 2002;78:308-309.
15. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12:80-96. (Pubitemid 29055954)
16. Dhingra S, Roseblade CK. Boric acid for refractory Candida glabrata vaginitis. J Obstet Gynaecol 2006;26:584. (Pubitemid 44454481)
17. Guaschino S, De Seta F, Sartore A, et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2001;184:598-602. (Pubitemid 32234972)
18. Nyirjesy P, Alexander AB, Weitz MV. Vaginal Candida parapsilosis: Pathogen or bystander? Infect Dis Obstet Gynecol 2005;13:37-41. (Pubitemid 40676986)
19. Savini V, Catavitello C, Bianco A, Balbinot A, D'Antonio F, D'Antonio D. Azole resistant Candida glabrata vulvovaginitis treated with boric acid. Eur J Obstet Gynecol Reprod Biol 2009;147:112.
20. Shinohara YT, Tasker SA. Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS. J Acquir Immune Defic Syndr Hum Retrovir 1997;16:219-220. (Pubitemid 27519936)
21. Silverman NS, Morgan M, Nichols WS. Candida lusitaniae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid. Infect Dis Obstet Gynecol 2001;9:245-247. (Pubitemid 34142845)
22. Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: Retrospective review of boric acid therapy. Clin Infect Dis 1997;24:649-652. (Pubitemid 27143559)
23. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297-1300. (Pubitemid 37542161)
24. Swate TE, Weed JC. Boric acid treatment of vulvovaginal candidiasis. Obstet Gynecol 1974;43:893-895.
25. Van Slyke KK, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. Am J Obstet Gynecol 1981;141:145-148. (Pubitemid 11018281)
26. Jovanovic R, Congema E, Nguyen HT. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis. J Reprod Med 1991;36:593-597.
27. Sood G, Nyirjesy P, WeitzMV, Chatwani A. Terconazole cream for non-Candida albicans fungal vaginitis: Results of a retrospective analysis. Infect Dis Obstet Gynecol 2000;8:240-243. (Pubitemid 32114473)
28. Kennedy M.A. Sobel J.D. Vulvovaginal candidiasis caused by non-albicans candida species: New insights. Curr. Infect. Dis. Rep. 2010 12 465-470
29. Sobel JD. Vaginitis. N Engl J Med 1997;337:1896-1903. (Pubitemid 28053998)
30. Ferrer J. Vaginal candidosis: Epidemiological and etiological factors. Int J Gynaecol Obstet 2000;71(Suppl 1):S21-27.
31. Mitchell H. Vaginal discharge-Causes, diagnosis, and treatment. BMJ 2004;328:1306-1308.
32. Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: Epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002;35:1066-1070. (Pubitemid 35239466)
33. Spinillo A, Capuzzo E, Egbe TO, Baltaro F, Nicola S, Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol 1995;85:993-998.
34. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002;99:419-425. (Pubitemid 34188402)
35. Martens MG, Hoffman P, El-Zaatari M. Fungal species changes in the female genital tract. J Low Genit Tract Dis 2004;8:21-24. (Pubitemid 38185937)
36. Spinillo A, Capuzzo E, Acciano S, De Santolo A, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 1999;180: 14-17. (Pubitemid 29088381)
37. Horowitz BJ, Giaquinta D, Ito S. Evolving pathogens in vulvovaginal candidiasis: Implications for patient care. J Clin Pharmacol 1992;32:248-255.
38. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992;14(Suppl 1): S148-153.
39. Bohannon NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care 1998;21:451-456. (Pubitemid 28101084)
40. Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003;101:548-556. (Pubitemid 36288497)
41. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000;61:3306-3312.
42. Spinillo A, Pizzoli G, Colonna L, Nicola S, De Seta F, Guaschino S. Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol 1993;81:721-727. (Pubitemid 23137242)
43. Siegel E, Wason S. Boric acid toxicity. Pediatr Clin North Am 1986;33:363-367. (Pubitemid 16075379)
44. Jansen JA, Andersen J, Schou JS. Boric acid single dose pharmacokinetics after intravenous administration to man. Arch Toxicol 1984;55:64-67. (Pubitemid 14101572)
45. Van Slyke KK, Michel VP, Rein MF. The boric acid powder treatment of vulvovaginal candidiasis. J Am Coll Health Assoc 1981;30:107-109. (Pubitemid 12130087)
46. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59:1-110.
47. Schillinger BM, Berstein M, Goldberg LA, Shalita AR. Boric acid poisoning. J Am Acad Dermatol 1982;7:667-673. (Pubitemid 12000537)
48. Fail PA, Chapin RE, Price CJ, Heindel JJ. General, reproductive, developmental, and endocrine toxicity of boronated compounds. Reprod Toxicol 1998;12:1-18. (Pubitemid 29108281)
49. Acs N, Banhidy F, Puho E, Czeizel AE. Teratogenic effects of vaginal boric acid treatment during pregnancy. Int J Gynaecol Obstet 2006;93:55-56.
50. Drugstore.com Available at www.drugstore.com Accessed March 6, 2011.